Close Menu

    Subscribe to Updates

    Get the latest creative news from Healthradar about News,Health and Gadgets.

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    What's Hot

    Congo’s health ministry declares new Ebola outbreak

    5. September 2025

    At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves

    4. September 2025

    GLP-1 Drugs Help Prevent Hospitalization, Early Death

    4. September 2025
    Facebook X (Twitter) Instagram
    Facebook X (Twitter) Instagram Pinterest Vimeo
    healthradar.nethealthradar.net
    • Home
    • Ai
    • Gadgets
    • Health
    • News
    • Contact Us
    Contact
    healthradar.nethealthradar.net
    Home»Health»GLP-1 Drugs Help Prevent Hospitalization, Early Death
    Health

    GLP-1 Drugs Help Prevent Hospitalization, Early Death

    HealthradarBy Healthradar4. September 2025Keine Kommentare5 Mins Read
    Share Facebook Twitter Pinterest LinkedIn Tumblr Reddit Telegram Email
    GLP-1 Drugs Help Prevent Hospitalization, Early Death
    Share
    Facebook Twitter LinkedIn Pinterest Email


    Injectable weight loss drugShare on Pinterest
    Weight loss drugs could help improve health outcomes in people with heart failure. The Good Brigade/Getty Images
    • Researchers report that the weight loss drugs semaglutide and tirzepatide can reduce the risk of hospitalization and death by 40% in people with a common type of heart failure.
    • Experts say this large cohort study strengthens the case for using these GLP-1 medications in people with this heart condition.
    • Regular exercise, a balanced diet, and quality sleep are important in maintaining good heart health.

    Two widely used weight loss drugs could significantly reduce the risk of complications in people with the most common type of heart failure

    The findings show that semaglutide, commonly sold under the brand names Ozempic, Wegovy, and Rybelsus, produced similar benefits to those produced by tirzepatide, commonly sold under the brand names Zepbound and Mounjaro.

    Semaglutide and tirzepatide reduced the risk of hospitalization for HFpEF and all-cause mortality by 40% compared to subjects who took the blood sugar medication sitagliptin, commonly sold under the brand name Januvia.

    The researchers looked at five cohort studies that used data from healthcare claims in the United States between 2018 and 2024. Eligibility criteria were then expanded to evaluate treatment effects in patients typically treated in clinical practice. Finally, a head-to-head comparison of tirzepatide and semaglutide was implemented with a follow-up of 52 weeks.

    In all, the researchers examined 58,000 people in a semaglutide versus sitagliptin comparison. Another 11,000 people were in a group that compared tirzepatide and sitagliptin, while 28,000 patients were studied in a semaglutide versus tirzepatide comparison.

    “These findings complement early results from small clinical trials and support the use of semaglutide and tirzepatide in patients with cardiometabolic heart failure with preserved ejection fraction,” the authors wrote.

    “This study further strengthens the case for using GLP-1 agonists in obese patients with HFpEF, a type of heart failure that is associated with significant morbidity and mortality,” said Pooja Prasad, MD, an assistant clinical professor in the Department of Advanced Heart Failure & Transplant Cardiology at the University of California San Francisco.

    “While recent randomized clinical trials have rightly generated a lot of interest in GLP-1 agonists, having these results, specifically reduction in the composite outcome of heart failure hospitalizations and all-cause mortality, replicated in a large cohort study will likely increase their utilization even before we see a change in guidelines,” she told Healthline.

    Heart failure with preserved ejection fraction (HFpEF) affects about 3 million people in the United States and more than 30 million people worldwide.

    People with HFpEF are hospitalized an estimated 1.4 times per year and have an annual mortality rate of approximately 15%.

    Experts said the new research opens up the possibility of new treatments for people with this form of heart failure.

    “As this condition is the most common form of heart failure and is a disease with limited treatment options, these study results offer a tremendous opportunity for us to better manage patients with this diagnosis,” said Cheng-Han Chen, MD, an interventional cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA.

    “These findings are important as they may broaden the indications for these medications and benefit a larger patient population,” added Mir Ali, MD, a general surgeon and bariatric surgeon as well as the medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA.

    Ali noted, however, that the study focused on people with high body mass index (BMI) readings. He said he’d like to see research done on the benefits of the weight loss medications on people with this heart condition who don’t have obesity or type 2 diabetes.

    “A study separating the weight loss effects (and improvement in diabetes) from other benefits, and elucidating the mechanism, would be helpful to further ascertain how these drugs are working to reduce heart failure,” he told Healthline.

    The Centers for Disease Control and Prevention (CDC) estimates that the prevalence of obesity among adults in the United States is about 40%.

    “Obesity affects every organ system in the body — from diabetes, heart disease, arthritis and even cancer. So, it is clear that reducing weight can improve or reverse the deleterious effects of obesity,” said Ali.

    “Through a variety of mechanisms, metabolic syndrome increases our risk for cardiovascular disease, which can manifest as both acute and chronic blockages in the arteries supplying blood to our heart, strokes, heart rhythm abnormalities, and heart failure (weakness and stiffness of the heart muscle).”

    “The GLP1 [weight loss] drugs are the best available medications for treatment of obesity. If the patient meets the criteria for surgery, that is even more effective,” Ali said.

    “We need to stop thinking of HFpEF as purely a cardiac disease,” added Prasad. “It is a consequence of metabolic syndrome, and treating it requires addressing metabolic syndrome, of which obesity is one key component.”

    Chen told Healthline there are a number of lifestyle factors people can adopt to improve their cardiovascular health. They include:

    • regular physical activity
    • eating a healthy balanced diet
    • getting an adequate amount of quality sleep
    • maintaining a healthy weight
    • avoiding tobacco and alcohol
    • controlling blood pressure and cholesterol numbers

    Experts say a heart-healthy diet should avoid ultra-processed foods, sugars, and unhealthy fats.

    • leafy green vegetables
    • whole grains
    • berries
    • beans
    • tomatoes
    • almonds

    Ali added that it’s essential that people adopt healthy habits, even if they are taking weight loss medications.

    “Patients need to realize that counseling, medications, and even surgery are tools to help the patient adopt a healthier diet and lifestyle, and like any other tool, if used properly, it works well,” he said. “However, it still requires the proper effort on the part of the patient.”



    Source link

    death drugs Early GLP1 heart failure glp-1 drugs weight loss Hospitalization prevent
    Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
    Previous ArticleRenal denervation gets strong backing from cardiologists ahead of Medicare coverage decision
    Next Article At Senate hearing, lawmakers express dissatisfaction with RFK Jr.’s vaccine moves
    ekass777x
    Healthradar
    • Website

    Related Posts

    Health

    Congo’s health ministry declares new Ebola outbreak

    5. September 2025
    Health

    Dexcom to lay off about 350 people

    4. September 2025
    Health

    To circumvent RFK Jr. on vaccines, Democrats and blue states start getting creative

    4. September 2025
    Add A Comment
    Leave A Reply Cancel Reply

    Top Posts

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202560 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202523 Views

    Linea Expands AI-Powered Heart Failure Care Solution

    6. August 202519 Views

    Neurode wants to treat and track ADHD symptoms through a wearable headband

    1. Juni 20259 Views
    Stay In Touch
    • Facebook
    • YouTube
    • TikTok
    • WhatsApp
    • Twitter
    • Instagram
    Latest Reviews

    Subscribe to Updates

    Bitte aktiviere JavaScript in deinem Browser, um dieses Formular fertigzustellen.
    Wird geladen
    About Us

    Welcome to HealthRadar.net — your trusted destination for discovering the latest innovations in digital health. We are dedicated to connecting individuals, healthcare professionals, and organizations with cutting-edge tools, applications

    Most Popular

    Garmin Venu 4: Everything we know so far about the premium smartwatch

    7. August 202560 Views

    The Top 3 Tax Mistakes High-Earning Physicians Make

    7. August 202523 Views
    USEFULL LINK
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    QUICK LINKS
    • Ai
    • Gadgets
    • Health
    • News
    • About Us
    • Contact Us
    • Disclaimer
    • Privacy Policy
    Copyright© 2025 Healthradar All Rights Reserved.

    Type above and press Enter to search. Press Esc to cancel.